Since all of the aforementioned events are characteristics of SLE immune cells, the autoantibody-producing PCs, XBP1, Blimp1, and OXPHOS may be potential therapeutic targets for SLE. The gene discussed is PRDM1; the disease is systemic lupus erythematosus.